An unpublished study of 3,855 women presented at the Menopause Society meeting found the gap held for semaglutide users. Experts caution it shows an association only.
Recap by typeshit. Full story at Healthline.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
An explainer on which weight loss medicines Novo Nordisk makes and its main product lineup, from the outlet's ongoing GLP-1 series.
Fractyl will prioritize weight maintenance after GLP-1 treatment, while EyePoint narrows in on diabetes-related vision loss.
Loading…